This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Algie C. Brown, MD
817 Douglas Rd Atlanta, GA 30342

Arch Dermatol. 1985;121(3):308-309.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Claudy and Gagnaire¹ reported hair regrowth after treatment with systemic psoralens and UV-A (PUVA) in 64% (11 of 17) patients with alopecia areata (AA). Endocrine disorders were not reported, and the racial background (ie, white or nonwhite) of the seven women and 16 men, who were selected for treatment without apparent bias, was not identified. The reproductive history (fertility, surgical castration, genital abnormalities, gonadal autoantibodies) was not determined. Treatment results were presumed to be based on alleviation of a complex immunomodulatory mechanism involving the hair bulb. Topical PUVA therapy was recommended in our patients with AA due to the frequent association of AA with vitiligo. We believe that age, skin type, endocrine disease, and genetic predisposition to poliosis, AA, vitiligo, or endocrinopathy could influence the response to therapy.^2-5

In the study by Claudy and Gagnaire,¹ the success of PUVA treatment was primarily segregated between . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?